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Abstract
The PI3K–AKT pathway is expected to be a therapeutic target for non-small cell lung cancer 
(NSCLC) treatment. We previously reported that a novel PI3K inhibitor iMDK suppressed 
NSCLC cells in vitro and in vivo without harming normal cells and mice. Unexpectedly, iMDK 
activated the MAPK pathway, including ERK, in the NSCLC cells. Since iMDK did not eradicate 
such NSCLC cells completely, it is possible that the activated MAPK pathway confers resistance 
to the NSCLC cells against cell death induced by iMDK. In the present study, we assessed 
whether suppressing of iMDK-mediated activation of the MAPK pathway would enhance anti-
tumorigenic activity of iMDK. PD0325901, a MAPK inhibitor, suppressed the MAPK pathway 
induced by iMDK and cooperatively inhibited cell viability and colony formation of NSCLC cells 
by inducing apoptosis in vitro. HUVEC tube formation, representing angiogenic processes in 
vitro, was also cooperatively inhibited by the combinatorial treatment of iMDK and PD0325901. 
The combinatorial treatment of iMDK with PD0325901 cooperatively suppressed tumor growth 
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and tumor-associated angiogenesis in a lung cancer xenograft model in vivo. Here, we demonstrate 
a novel treatment strategy using iMDK and PD0325901 to eradicate NSCLC.
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Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide [1]. Recent 
discoveries of molecularly targeted therapies, including erlotinib/gefitinib for EGFR-mutant 
NSCLC [2,3] and crizotinib/ceritinib for ALK-fusion NSCLC [4,5] have demonstrated that 
such therapies using small molecule drugs extend survival of NSCLC patients significantly, 
compared to conventional chemotherapy [6,7]. In addition to EGFR-mutant or ALK-fusion 
NSCLCs, projection for RET-fusion and ROS1-fusion NSCLCs mortality are also 
considered to be favorable since they can be targeted by small molecules, such as crizotinib 
[7,8]. A drawback of current therapy for NSCLC is that there is no effective treatment for 
KRAS-mutant NSCLC; the most common type in Caucasians and the second most common 
type in Asians [9], and squamous NSCLC [10]. Molecularly targeted therapies for KRAS-
mutant NSCLC have been tested [11,12]. For example, inhibition of MEK (a MAPKK; 
downstream of KRAS) by selumetinib, a MEK inhibitor, in addition to docetaxel (a 
chemotherapeutic drug) extended survival of KRAS-mutant NSCLC patients by 4 months 
compared to docetaxel alone. However, selumetinib plus docetaxel caused more adverse 
events than docetaxel alone [13], indicating that further improvements in this therapeutic 
strategy are needed to extend survival and reduce the adverse events associated with KRAS-
mutant NSCLC.
In addition to the KRAS–MAPK pathway, the KRAS–PI3K–AKT pathway is considered to 
contribute to KRAS lung tumorigenesis [14]. While not mutually exclusive, these pathways 
often interact with each other [15]. For example, a PI3K inhibitor PI-103 inhibited the PI3K 
pathway while activating the MAPK pathway [16], suggesting a potential mechanism for 
tumor survival by the compensatory activation of an alternative tumorigenic pathway. We 
recently reported a novel PI3K inhibitor iMDK, which was originally identified as a small 
molecule inhibiting the growth factor MDK (also known as midkine or MK) [17]. While its 
direct targets are unknown, iMDK inhibited phosphorylation of PI3K and AKT, indicating 
that iMDK serves as a PI3K inhibitor [17]. Similarly to PI-103 [16], iMDK activated 
phosphorylation of ERK and P38MAPK while inhibiting the PI3K pathway [17]. Since the 
combined inhibition of the PI3K and MAPK pathways by PI-103 and a MAPK inhibitor 
PD0325901 enhanced cell killing of NSCLC [16], in the present study, we tested whether 
the novel PI3K inhibitor iMDK further enhanced cell death of NSCLC in the presence of 
PD0325901. Combined treatment of iMDK and PD0325901 significantly suppressed tumor 
growth of NSCLC, including KRAS-mutant NSCLC and squamous NSCLC. The 
combinatorial treatment also inhibited endothelial cell-mediated angiogenesis, a requirement 
for tumor progression in vitro and in vivo. Here, we demonstrate a novel strategy to treat 
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NSCLC by simultaneously targeting both PI3K and MAPK pathways by iMDK and 
PD0325901.
Materials and methods
Reagents
3-[2-(4-fluorobenzyl)imidazo[2,1–b][1,3]thiazol-6-yl]-2H-chromen-2-one (here after termed 
iMDK) purchased from ChemDiv (San Diego, CA) and MEK inhibitor PD0325901 obtained 
from Selleck Chemicals (Houston, TX) were dissolved in DMSO.
Cell lines and culture conditions
H441 (lung adenocarcinoma; KRASG12V), H2009 (non-small cell carcinoma; KRASG12A), 
A549 (lung carcinoma; KRASG12S) and H520 (lung squamous cell carcinoma; KRASWT) 
were obtained from the American Type Culture Collection (Manassas, VA) and grown in 
high glucose Dulbecco’s modified Eagle medium (H441 and A549) or RPMI 1640 (H2009 
and H520) supplemented with 10% heat-inactivated fetal bovine serum. Cell information 
was obtained from COSMIC (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). 
Human umbilical vein endothelial cells (HUVECs) pur chased from Life Technologies 
(Grand Island, NY) were grown in HUVEC growth medium (MCDB-104 medium 
supplemented with 10 ng/ml EGF, 100 μg/ml heparin, 100 ng/ml endothelial cell growth 
factor and 10% heat-inactivated fetal bovine serum). All cell lines were cultured in 10% 
CO2 at 37 °C.
Immunoblot analysis
Cells were lysed in ice-cold M-PER lysis buffer purchased from Thermo Fisher Scientific 
(Rockford, IL). Cell lysates were clarified by centrifugation (20 min at 15,000g at 4 °C) and 
protein concentration determined using the BCA protein assay (Thermo Fisher Scientific). 
Equal amounts of protein were separated on an SDS-PAGE gel. The gel was 
electrophoretically transferred to a Hybond PVDF transfer membrane (GE. Healthcare Ltd., 
Piscataway, NJ) and incubated with primary and secondary antibodies according to the 
Supersignal® West Pico chemiluminescence protocol (Pierce, Rockford, IL). Antibody 
specific for β-actin antibody was obtained from Sigma (St. Louis, MO). Antibody specific 
for AKT, phosphorylated-AKT (Ser473), ERK, and phosphorylated-ERK (Ser473) were 
obtained from Cell Signaling Technology (Beverly, MA). Secondary horseradish 
peroxidase-conjugated antibodies were obtained from Jackson Immunoresearch Laboratories 
(West Grove, PA).
Cell viability assay
H441 cells and H2009 cells were plated in 96-well plates at a density of 1.5 × 103 cells and 
cultured at 37 °C for 24 h. H441 and H2009 cells were treated with or without iMDK (2.5 
μM) in the presence or absence of PD0325901 (0.5 μM). H520 cells were treated with or 
without iMDK (0.125 μM) in the presence or absence of PD0325901 (0.25 μM). A549 cells 
were treated with or without iMDK (0.25 μM) in the presence or absence of PD0325901 
(0.125 μM). Cells were treated for 72 h. Viable cells were assessed by WST-1 assays (Roche 
Molecular Biochemicals, Laval, Quebec, Canada) according to the manufacturer’s protocol.
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Colony formation assay
Cells were first plated at a density of 5 × 104 cells for H441 and 1 × 105 cells for H2009 
cells per well in 12-well plates 24 h before treatment. H441 cells were treated with iMDK at 
a concentration of 1 μM and/or PD0325901 at a concentration of 500 nM for 24 h and then 
released from the dish by incubation with trypsin/EDTA, counted, plated in triplicate at a 
density of 5 × 103 cells in six-well plates for 14 days. H2009 cells were treated with iMDK 
and/or PD0325901 at a concentration of 1 μM for 24 h and then released from the dish by 
incubation with trypsin/EDTA, counted, plated in triplicate at a density of 1 × 103 cells in 
six-well plates for 14 days. The cells were fixed with 100% methanol and allowed to air dry. 
The cells were then stained with 0.1% crystal violet. Colonies (a group of aggregated cells 
numbering at least 50) were then counted. The mean number of the control group was 
arbitrarily set to 100%, and all other numbers were normalized and percentage-specific 
cytotoxicity compared to colony formation in the control group was calculated.
Flow cytometric analysis for activated caspase-3
H441 cells were plated in 12-well plates at a density of 1 × 105 cells per well 1 day before 
the treatments. Cells were treated with iMDK (10 nM) or PD0325901 (10 nM) alone, or 
iMDK (10 nM) in combination with PD0325901 (10 nM). After 72 h, cells were harvested 
and washed twice with PBS. Cleaved caspase 3 was labeled in situ with phycoerythrin (PE)–
conjugated anti-activated caspase-3 antibodies purchased from BD Bioscience (San Jose, 
CAs) and analyzed by FACS Verse (BD Bioscience)[18,19].
TUNEL staining
Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) 
staining was performed to detect apoptosis using the DeadEnd colorimetric TUNEL system 
(Promega, Madison, WI) according to the manufacturer’s protocol.
HUVEC tube formation assay
HUVECs were treated with iMDK (10 μM) and/or PD0325901 (10 μM) for 5 h and a tube 
formation assay was performed using an in vitro angiogenesis kit (Millipore Corp. Bedford, 
MA). Tube formation was quantified by measuring the total length of the tube network and 
the number of branching points using Image J software (NIH, Bethesda) [20,21].
Mouse experiments
The experimental protocol was approved by the Ethics Review Committee for Animal 
Experimentation of Okayama University Graduate School of Medicine and Dentistry (Ethics 
Committee reference number: OKU-2013104). Human lung cancer xenografts were 
established in 6-wk-old female BALB/c nude mice (Charles River Laboratories Japan, 
Kanagawa, Japan) by subcutaneous (s.c.) inoculation of H441 cells (1 × 106/50 μl) into the 
right dorsal flank. The mice were randomly assigned into four groups (n=8 per group) 9 
days after tumor inoculations. The mice were intraperitoneally injected with 100 μl solution 
containing iMDK (9 mg/kg) everyday and/or orally administered PD0325901 (5 mg/kg) in 
0.5% [w/v] methylcellulose solution with 0.2% [v/v] polysorbate 80 [Tween 80] five times 
per week (on days 1, 2, 3, 4, 5, 7, 8, 9, 10, 11). DMSO was intraperitoneally injected and 
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methylcellulose solution with polysorbate 80 was orally administered in the control group. 
Tumors were measured every day, and tumor volume was calculated as a × b2 × 0.5, where 
a and b were large and small diameters, respectively. On day 11, all mice were sacrificed 
and tumors were removed and prepared for histology.
For immunohistochemistry, sections were sequentially depar-affinized through a series of 
xylene, graded ethanol, and water immersion steps. After being autoclaved in 0.2% citrate 
buffer for 15 min, sections were incubated with 3% hydrogen peroxide for 30 min to block 
endogenous peroxidase activity. The antibodies for CD31/PECAM-1 were obtained from 
Abcam. Specimens were incubated overnight at 4 °C with a 1:100 dilution of antibody 
followed by three washes with TBS. The slides were treated with streptavidin-biotin 
complex (Envision System labeled polymer, horseradish peroxidase [HRP], Dako, 
Carpinteria, CA) for 60 min at a dilution of 1:100. Immunoreactions were visualized using a 
3,39-diaminobenzidine (DAB) substrate-chromogen solution (Dako Cytomation LiquidDAB 
Substrate Chromogen System, Dako) and counterstained with hematoxylin. Sections were 
immersed in an ethanol and xylene bath and mounted for examination.
Ras activation assay
H441 cells were treated with iMDK (250 nM and 500 nM) or PD0325901 (50 nM and 250 
nM) for 6 h and 24 h. Cells were rinsed in PBS before cell lysis. Ras activation was 
determined using a RasGTPase Chemi ELISA kit, according to manufacturer’s protocol 
(Active Motif, Carlsbad, CA).
Statistical analysis
Significance of group differences was evaluated using ANOVA for multiple comparisons. 
Statistical significance was defined as p<0.05 (#).
Results
PD0325901 inhibited activation of ERK induced by iMDK treatment in H441 lung 
adenocarcinoma cells
In the previous study, we demonstrated that iMDK suppressed the PI3K–AKT pathway (12 
h after treatment) while inducing the MAPK pathway (48 h after treatment), as detected by 
the phosphorylation of ERK (MAPK), in H441 lung adenocarcinoma cells that carry a KRAS 
mutation (KRASG12V) [22]. Phosphorylated ERK (p-ERK) was slightly increased less than 1 
h after treatment (Supplemental Fig. 1); however, p-ERK was robustly increased 72 h after 
treatment (Fig. 1A), suggesting that the effect of iMDK on the MAPK pathway in a short 
time is limited. RAS-GTP levels were not affected by iMDK (less than 24 h; Supplemental 
Fig. 2). These results suggest that iMDK primarily targets the PI3K pathway but not KRAS 
itself, which in turn influences alternative tumorigenic pathways. Induction of an alternative 
tumorigenic pathway after suppression of a tumorigenic pathway by therapeutic cancer 
drugs is considered to be a mechanism by which tumors evade cell death from the 
molecularly targeted drugs. Thus, a combinatorial treatment using drugs targeting multiple 
pathways may be required to block tumor cell resistance [15,23–25]. In order to test this 
concept, we assessed whether the MAPK pathway activated by iMDK is suppressed by 
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PD0325901, a MEK (MAPKK) inhibitor, in H441 cells. As shown in Fig. 1B, PD0325901 
suppressed iMDK-induced phosphorylation of ERK in a dose-dependent fashion. These 
results indicate that the combinatorial treatment of iMDK with PD0325901 simultaneously 
inhibits two major KRAS tumorigenic pathways in H441 cells.
PD0325901 enhanced iMDK-mediated suppression of cell proliferation and colony 
formation in H441 cells
Having demonstrated that the combinatorial treatment of iMDK and PD0325901 inhibited 
both the PI3K pathway and the iMDK-mediated activation of the MAPK pathway in H441 
cells carrying KRASG12V (Fig. 1), we assessed whether the combinatorial treatment would 
inhibit growth of H441 cells as well as other KRAS mutated NSCLC cells, including H2009 
(non-small cell carcinoma; KRASG12A) and A549 (lung carcinoma; KRASG12S) cells, and 
KRAS wild type H520 (lung squamous cell carcinoma; KRASWT) cells. First, we assessed 
whether iMDK inhibited the PI3K pathway not only in H441 cells but also other cells, 
including H2009 and H520 cells. As shown in Supplemental Fig. 3, AKT (downstream of 
PI3K) activation was inhibited by iMDK, indicating that iMDK inhibits the PI3K pathway 
in a broad range of NSCLC cells regardless of KRAS mutations. Next, we treated the cells 
with iMDK and/or a MAPK inhibitor PD0325901. As shown in Fig. 2A, PD0325901 further 
inhibited iMDK-mediated suppression of cell viability in KRAS mutated H441 and H2009 
cells as well as KRAS wild type H520 cells. Though iMDK alone did not inhibit cell 
viability of A549 cells, the combinatorial treatment of iMDK with PD0325901 significantly 
inhibited that of A549 cells compared to the single treatment of PD0325901. As shown 
previously [17], MDK is expressed in H441, H2009 and H520 cells but not in A549 cells. 
These results indicate that the combinatorial treatment inhibits cell viability of NSCLC cells 
independently of KRAS mutations or MDK expression. In addition to cell viability, colony 
formation of H441 and H2009 cells were also significantly reduced by the combinatorial 
treatment compared to either iMDK or PD0325901.
Combinatorial treatment of iMDK with PD0325901 increased apoptosis in H441 cells
In order to analyze the mechanism by which PD0325901 enhances iMDK-mediated cell 
growth inhibition in the NSCLC cells, we measured the degree of apoptosis after the 
combinatorial treatment in H441 cells by quantifying activated caspase-3 and TUNEL 
positive cells, which are markers of apoptosis. As shown in Fig. 3, flow cytometric analysis 
demonstrated that single use of iMDK or PD0325901 (10 nM) did not induce activation of 
caspase-3 (Fig. 3A). Combinatorial treatment with iMDK and PD0325901 synergistically 
increased levels of activated caspapse-3. Combinatorial treatment significantly increased the 
number of TUNEL positive cells compared to either iMDK or PD0325901 alone (Fig. 3B). 
These results indicate that the inhibition of H441 cell growth by the combinatorial treatment 
of iMDK with PD0325901 is likely attributed to apoptosis.
iMDK with PD0325901 suppressed tube formation of HUVECs in vitro
Endothelial cells contribute to tumor progression by creating blood vessels leading to 
angiogenesis to fuel tumor cells [26]. We sought to determine whether the combinatorial 
treatment with iMDK and PD0325901 influences not only NSCLC cells but also 
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angiogenesis constituted from such endothelial cells. First, using TUNEL staining, we 
assessed whether the treatment of iMDK, PD0325901 or both in combination would induce 
cell death in HUVEC (Human Umbilical Vein Endothelial Cells). iMDK, PD0325901 or a 
combination of the two did not induce cell death in HUVEC in vitro (Fig. 4A), indicating 
that iMDK does not cause apoptosis in normal cells, consistent with our previous report 
[17]. Next, we assessed whether treatment with iMDK, PD0325901 or both in combination 
influenced angiogenesis by assessing tube formation in HUVECs, which mimics 
angiogenesis in vitro. Neither iMDK nor PD0325901, when used alone, inhibited 
angiogenesis as assessed by HUVEC tube formation. In contrast, combinatorial treatment 
with iMDK and PD0325901 significantly disrupted tube formation 5 h after treatment (Fig. 
4B). Protein expression of MDK was not detected in HUVEC cells (data not shown), 
indicating that the combinatorial treatment disrupts the tube formation independently of 
MDK. These results indicate that simultaneous inhibition of the PI3K and MAPK pathways 
suppresses angiogenesis as well as tumor cell growth, both of which are required for tumor 
growth.
The combinatorial treatment of iMDK with PD0325901 significantly suppressed tumor 
growth and tumor-associated angiogenesis in lung Cancer xenograft model in vivo
In order to determine whether combinatorial treatment of iMDK with PD0325901 
cooperatively suppresses lung tumor growth in vivo, we treated nude mice carrying 
xenograft tumors derived from H441 cells with iMDK and/or PD0325901. As shown in Fig. 
5A, tumor growth was significantly suppressed after daily intraperitoneal injection of iMDK 
or oral administration of PD0325901 5 times a week. The combinatorial treatment of iMDK 
with PD0325901 further inhibited the tumor growth compared to either iMDK or 
PD0325901 alone. Angiogenesis in the xenografted tumor, which was assessed by the 
expression of CD31/PECAM-1, was also cooperatively inhibited by the combinatorial 
treatment of iMDK with PD0325901 compared to either iMDK or PD0325901 (Fig. 5B and 
C). These results indicate that the combinatorial treatment of iMDK with PD0325901 
significantly suppresses tumor growth and tumor-associated angiogenesis of NSCLC in vivo.
Discussion
Molecularly targeted therapies are extending survival of some NSCLC patients compared to 
conventional chemotherapy [7]; however, a therapeutic target for KRAS-mutant NSCLC and 
squamous NSCLC, which are the most common lung cancers, has not been clinically 
established. A recent clinical trial using a MAPK inhibitor selumetinib, a molecularly 
targeted drug, in combination with docetaxel (chemotherapeutic [non-molecularly targeted] 
drug) extended survival by 4 months for patients whose lung adenocarcinomas carry KRAS 
mutations compared to those using docetaxel alone; however, the combinatorial treatment 
resulted in increased incidence of adverse effects compared to docetaxel only treatment [13]. 
There is an urgent need for better therapeutic strategies to treat NSCLCs whose molecular 
targets are not known.
Previously, we reported that iMDK, which suppresses the expression of MDK, inhibited the 
PI3K pathway and in turn suppressed the growth of KRAS-mutant NSCLC cells [17]. 
Ishida et al. Page 7
Exp Cell Res. Author manuscript; available in PMC 2015 July 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Unexpectedly, iMDK also activated the MAPK pathway, which suggests the compensatory 
activation of an alternative tumorigenic pathway for KRAS-mutant NSCLC cell survival. In 
the present study, killing of KRAS-mutant NSCLC cells was enhanced by inhibiting iMDK-
mediated activation of the MAPK pathway using PD0325901 in addition to iMDK-mediated 
suppression of the PI3K pathway. The combinatorial treatment was also effective in 
reducing tumor growth of KRAS wild type H520 squamous NSCLC cells, indicating that the 
combinatorial treatment can be applicable for different types of NSCLC. iMDK did not 
reduce body weight or cause toxicity in mice [17], suggesting that the combinatorial use of 
iMDK with PD0325901 or other MAPK inhibitors, such as selumetinib, might be superior to 
the combinatorial use of docetaxel and selumetinib to prevent the adverse effects. 
Combinatorial therapy with iMDK may also enable treatment using reduced amounts of a 
MAPK inhibitor. The simultaneous inhibition of both the PI3K and MAPK pathways by 
small molecule drugs was previously shown to suppress KRAS-mutant NSCLC in vitro and 
in vivo [15,27]. For example, the combinatorial use of NVP-BEZ235 (a PI3K inhibitor) and 
ARRY-142886 (a MAPK inhibitor) synergistically reduced Kras-mutant lung tumors in a 
transgenic mouse model [28]. NVP-BEZ235 is currently being tested for safety in clinical 
trials [29]. While both NVP-BEZ235 and iMDK inhibit the PI3K pathway, the chemical 
structure of iMDK is distinct from that of NVP-BEZ235, indicating that iMDK may 
influence the PI3K pathway in a manner distinct from NVP-BEZ235. Clinical development 
of iMDK or related compounds as a next generation PI3K drug may be useful.
Angiogenesis creates a tumor microenvironment that enhances tumor progression, 
developing new blood vessels consisting of endothelial cells and thereby supplies nutrients 
and oxygen to tumor cells [30]. Previously, we demonstrated in a xenograft mouse model 
using H441 cells that iMDK suppressed expression of CD31/PECAM-1, a marker of 
angiogenesis [17]. While iMDK suppresses angiogenesis in vivo, it remains unknown 
whether iMDK directly influences growth or activities of endothelial cells. In the present 
study, we sought to determine whether the combinatorial treatment of iMDK with 
PD0325901 suppressed angiogenesis. Tube formation assays using HUVEC (endothelial 
cells) recapitulate the angiogenesis process in vitro [31]. The combinatorial treatment of 
iMDK with PD0325901 suppressed HUVEC tube formation but not HUVEC growth 
compared to either iMDK or PD0325901 (Fig. 4). The combinatorial treatment also 
suppressed tumor-associated angiogenesis in the xenograft lung tumor derived from H441 
cells compared to those of treatment with a single compound in vivo (Fig. 5). These results 
suggest that the combinatorial treatment suppresses NSCLC growth by not only directly 
causing apoptosis of NSCLC cells but also by directly disrupting tumor-associated 
angiogenesis.
In summary, we demonstrated that the combinatorial treatment of a novel PI3K inhibitor 
iMDK with a MAPK inhibitor PD0325901 cooperatively suppressed the growth of NSCLC 
cells regardless of KRAS mutations or MDK expression. The combinatorial treatment also 
disrupted in vitro and in vivo angiogenesis that may influence the tumor-associated 
environment to limit tumor survival. The strategy using iMDK or related compounds with a 
MAPK inhibitor may be a promising approach to treat NSCLC whose molecular targets are 
not identified.
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. PD0325901 inhibited ERK1/2 phosphorylation induced by iMDK treatment in H441 lung 
adenocarcinoma cells
A. iMDK suppressed AKT phosphorylation in a dose-dependent manner (0–500 nM) in 
H441 lung adenocarcinoma cells after treatment for 72 h. In contrast, ERK1/2 
phosphorylation was increased by iMDK as assessed by immunoblot analysis.
B. PD0325901 (10–250 nM) suppressed ERK1/2 phosphorylation induced by iMDK (200 
nM) in H441 cells. Conversely, iMDK suppressed AKT phosphorylation induced by 
PD0325901. H441 cells were treated with iMDK in the presence or absence of PD0325901 
for 72 h.
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Fig. 2. Combination of iMDK and PD0320901 cooperatively suppressed cell viability and colony 
formation of NSCLC cells
A. PD0325901 enhanced growth inhibition in H441, H2009 and H520 and A549 NSCLC 
cells after iMDK treatment. Treatment conditions were described in Materials and Methods. 
Cell viability was assessed by the WST-1 assay 72 h after exposure to iMDK. Data are 
presented as % growth inhibition as described in Methods. Statistical significance was 
defined as p<0.05 (#).
B. Colony formation of H441 and H2009 cells treated with iMDK (1 μM) and/or 
PD0325901 (500 nM for H441 cells, 1 μM for H2009 cells). Fourteen days after the 
treatment, cells were fixed and stained with crystal violet. Representative images of 
experiments performed in triplicate are shown.
C. Mean colony number was derived from quantitation of triplicate dishes for each treatment 
and arbitrarily set to 100%. Data are shown relative to controls. Statistical significance was 
defined as p<0.05 (#).
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Fig. 3. PD0325901 enhanced apoptosis induced by iMDK in H441 lung adenocarcinoma cells
A. H441 lung adenocarcinoma cells were fixed and stained with anti-activated caspase 3 
antibodies 72 h after iMDK (10 nM) and/or PD0325901 (10 nM) and analyzed by flow 
cytometry. The percentage of cells staining for active caspase-3 is indicated.
B. PD0325901 enhanced apoptosis induced by iMDK in H441 cells. Cells were treated for 
72 h at a concentration of 10 nM iMDK. TUNEL staining was performed as described in 
Methods. Statistical significance was defined as p<0.05 (#).
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Fig. 4. iMDK suppressed angiogenesis with PD0325901 in vitro
A. Treatment of HUVEC cells with iMDK, PD0325901 or a combination of the two did not 
induce cell death as detected by TUNEL staining. Cells were treated for 5 h at a 
concentration of 10 μM. TUNEL staining was performed as described in Materials and 
methods.
B. Combinatorial treatment of iMDK with PD0325901 significantly inhibited tube formation 
of HUVECs. HUVEC cells were treated with iMDK (10 μM), PD0325901 (10 μM) or both 
for 5 h. Tube length was quantified as detailed in Materials and methods. Statistical 
significance was defined as p<0.05 (#).
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Fig. 5. The combination treatment of iMDK and PD0325901 effectively reduced lung tumor 
growth in a xenograft mouse model
A. Volume of the tumors derived from H441 lung adenocarcinoma cells was significantly 
reduced after the combination treatment with iMDK (9 mg/kg) and PD0325901 (5 mg/kg) 
compared to that of single compound in a xenograft mouse model. Eight mice were used in 
each group. Tumor volume was monitored every day after inoculation of H441 cells. Tumor 
growth is expressed as mean tumor volume; bars represent SD. Statistical significance was 
defined as p<0.05 (#).
B. Shown is an image of xenograft tumors derived from H441 cells, which are dissected 
from the xenograft mice 11 days after treatment with iMDK. Expression of an angiogenesis 
marker CD31/PECAM-1 was detected by immunohistochemistry (scale bar shows 200 μm).
C. Expression of CD31/PECAM-1 was significantly inhibited by the combination treatment 
of iMDK and PD0325901 compared to that of single compound treatment. Statistical 
significance was defined as p<0.05 (#).
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